About Pituitary tumor-transforming gene 1 protein-interacting protein
Pituitary tumor-transforming gene 1 protein-interacting protein (PTTG1IP) is a protein
from Homo sapiens identified by UniProt accession
P53801, 180 residues long.
MolForge cross-references it against 0 known binders and
59 disease associations.
Target properties
| Protein name | Pituitary tumor-transforming gene 1 protein-interacting protein |
|---|
| UniProt accession | P53801 |
|---|
| Gene | PTTG1IP |
|---|
| Organism | Homo sapiens |
|---|
| Length | 180 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (59)
Diseases linked to this target (Open Targets).
- high density lipoprotein cholesterol measurement · score 0.43
- serum gamma-glutamyl transferase measurement · score 0.41
- alcohol drinking · score 0.35
- alcohol consumption measurement · score 0.33
- mean corpuscular volume · score 0.33
- Red cell distribution width · score 0.33
- apolipoprotein A 1 measurement · score 0.33
- mean corpuscular hemoglobin · score 0.32
- serum alanine aminotransferase measurement · score 0.31
- mean corpuscular hemoglobin concentration · score 0.28
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P53801-F1 | alphafold | PREDICTED | 77.22 | — |
Amino-acid sequence (180 residues)
MAPGVARGPT PYWRLRLGGA ALLLLLIPVA AAQEPPGAAC SQNTNKTCEE CLKNVSCLWC NTNKACLDYP VTSVLPPASL CKLSSARWGV CWVNFEALII TMSVVGGTLL LGIAICCCCC CRRKRSRKPD RSEEKAMRER EERRIRQEER RAEMKTRHDE IRKKYGLFKE ENPYARFENN
Explore Pituitary tumor-transforming gene 1 protein-interacting protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets